Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results for ARIA
-0.40 (-3.71%)
After Hours: 10.37 -0.01 (-0.10%)
Oct 21, 7:40pm GMT-4  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.32 - 11.12
52 week 4.37 - 14.34
Open 10.80
Vol / Avg. 11.16M/7.92M
Mkt cap 1,994.81M
P/E     -
Div/yield     -
EPS -0.33
Shares 192.71M
Beta 1.87
Inst. own 70%
Nov 1, 2016
Q3 2016 ARIAD Pharmaceuticals Inc Earnings Release (Estimated) - 9:30am GMT-4 - Add to calendar
Sep 12, 2016
ARIAD Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference
Jul 28, 2016
Q2 2016 ARIAD Pharmaceuticals Inc Earnings Release
Jul 28, 2016
Q2 2016 ARIAD Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 161.24% -194.57%
Operating margin -17.12% -182.89%
EBITD margin - -172.15%
Return on average assets 78.20% -40.21%
Return on average equity - -
Employees 459 -
CDP Score - -


United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Officers and directors

Alexander J. Denner Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Paris Panayiotopoulos President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Executive Vice President, Treasurer
Age: 38
Bio & Compensation  - Reuters
Jennifer Lyn Herron Executive Vice President, Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
Jayne M. Gansler Senior Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 55
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs
Age: 48
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 51
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
George W. Bickerstaff III Independent Director
Age: 60
Bio & Compensation  - Reuters